Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 1 of 3 (33%) have an AI response strategy ready
Seqirus Inc. is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are spread across 3 distinct examiners and 2 distinct art units. This distribution indicates a complex prosecution landscape compared to portfolios with 1 action, as it involves 2 distinct art units and 3 distinct examiners. Practitioners must manage the 3 pending office actions with an eye toward technical consistency across the 2 distinct art units.
The busiest examiner, MOU, LIYUAN, is responsible for 1 busiest examiner pending action. Practitioners must coordinate strategies across the 2 distinct art units while addressing the specific requirements of the Biotechnology & Pharmaceuticals field for each of the 3 pending office actions. This multi-examiner environment requires a versatile approach to USPTO communications across the cases. The presence of 3 distinct examiners ensures that the portfolio's progress is not dependent on an individual's review style.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
| BASQUILL, SEAN M | 1 | 38.8% | +21.7% |
| CORNELIUS, CLAIRE ADRIENNE | 1 | 66.7% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037226 | MULTICISTRONIC RNA VACCINES AND USES THEREOF | CORNELIUS, CLAIRE ADRIENNE | 27d |
| 18702909 | IONIZABLE CATIONIC COMPOUND | MOU, LIYUAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18702909 | IONIZABLE CATIONIC COMPOUND | MOU, LIYUAN | — |
| 18695917 | IONIZABLE CATIONIC COMPOUNDS FOR MESSENGER RNA DELIVERY | BASQUILL, SEAN M | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18702909 | IONIZABLE CATIONIC COMPOUND | MOU, LIYUAN | 1645 | §102§103§112Other | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18695917 | IONIZABLE CATIONIC COMPOUNDS FOR MESSENGER RNA DELIVERY | BASQUILL, SEAN M | — | §103DP | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18037226 | MULTICISTRONIC RNA VACCINES AND USES THEREOF | CORNELIUS, CLAIRE ADRIENNE | 1672 | §103§112 | Final Rejection | 27d | AI Ready | May 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial